Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Accelerates Growth After Sage Acquisition, Near-Term Momentum Expected
![]() |
Supernus enters the remainder of 2025 with expanded commercial breadth and cash strength. Recent corporate moves and mixed but constructive technicals suggest near-term directional pressure with continued fundamental support. |









